EyePoint Pharmaceuticals News

EyePoint Pharmaceuticals Analyst Ratings

BenzingaMay 13 06:56 ET

EyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and Trials

TipRanksMay 13 06:25 ET

Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future Prospects

TipRanksMay 9 05:26 ET

Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating

MT NewswiresMay 8 10:48 ET

EyePoint Pharmaceuticals Analyst Ratings

BenzingaMay 8 07:01 ET

Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38

BenzingaMay 8 07:02 ET

Maintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study Setback

TipRanksMay 7 07:52 ET

EyePoint Pharmaceuticals Analyst Ratings

BenzingaMay 7 07:04 ET

Maintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in WAMD Market Despite NPDR Study Setback

TipRanksMay 6 17:15 ET

Bullish Buy Rating Reaffirmed for EyePoint Pharmaceuticals With a $39 Price Target

TipRanksApr 30 02:49 ET

EyePoint Pharmaceuticals Analyst Ratings

BenzingaMar 8 13:05 ET

HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target

BenzingaMar 8 13:06 ET

Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Clinical Trials and Market Expansion Potential

TipRanksMar 8 10:45 ET

Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)

TipRanksMar 7 20:51 ET

EyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy Rating

TipRanksMar 7 00:06 ET

EyePoint Pharmaceuticals Analyst Ratings

BenzingaFeb 16 18:47 ET

Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and EyePoint Pharmaceuticals (EYPT)

TipRanksFeb 16 08:30 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)

TipRanksFeb 7 10:50 ET

EyePoint Pharmaceuticals Earns Buy Rating Following Promising EYP-1901 Clinical Trial Results

TipRanksFeb 5 06:15 ET

EyePoint Pharmaceuticals Analyst Ratings

BenzingaJan 22 08:58 ET